Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOPHYLLIN vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to albumin; binding is nonlinear and decreases at higher serum concentrations.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.4-0.7 L/kg, approximating total body water (0.45 L/kg in adults). Vd is increased in neonates (0.6 L/kg) and decreased in obesity (0.3-0.4 L/kg) due to reduced lean body mass.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 90-100%; Oral sustained-release: 80-100% relative to immediate-release; Rectal solution: 100%; Rectal suppository: 60-80% (erratic).
Oral: 40-50%; Inhalation: 20-30%
For GFR <30 m L/min: reduce maintenance dose by 50%; consider monitoring serum concentrations.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 75%; Child-Pugh Class C: avoid use or use with extreme caution with 80% dose reduction.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
IV loading dose: 5-7 mg/kg over 20-30 minutes; maintenance IV infusion: 0.5-1 mg/kg/hour for ages 1-9 years, 0.4-0.7 mg/kg/hour for ages 9-16 years; oral: 10-20 mg/kg/day in divided doses every 6-8 hours, maximum 600 mg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Elderly patients: reduce loading dose to 4-5 mg/kg; maintenance dose 0.2-0.3 mg/kg/hour IV or 200-400 mg/day oral; monitor serum theophylline levels closely due to decreased clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None explicitly required by FDA, but use with caution due to narrow therapeutic index and potential for severe toxicity.
No FDA black box warning.
Narrow therapeutic index; monitor serum concentrations regularly. Risk of arrhythmias, seizures, and gastrointestinal bleeding. Use lower doses in heart failure, liver disease, and elderly. Avoid abrupt discontinuation due to withdrawal symptoms.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to xanthines, active seizure disorders, severe arrhythmias, and uncontrolled hyperthyroidism.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing theophylline levels. Limit caffeine intake (coffee, tea, cola) as it may add to theophylline's stimulant effects. High-fat meals may delay absorption; take consistently with or without food.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third trimesters: no known adverse fetal effects. However, use only if clearly needed.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excreted into breast milk; M/P ratio approximately 0.6-0.8. Relative infant dose is low (<10% of maternal weight-adjusted dose). No reports of adverse effects in breastfed infants. Caution advised in preterm or ill infants.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy reduces theophylline clearance by 30-50%, especially in the third trimester. Dose may need reduction by up to 50% to maintain therapeutic levels. Monitor levels closely and adjust accordingly. Postpartum clearance rapidly returns to prepregnancy levels, requiring dose increase to avoid subtherapeutic levels.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
LANOPHYLLIN is a fixed-dose combination of lansoprazole, a proton pump inhibitor, and theophylline, a methylxanthine bronchodilator. Monitor serum theophylline levels due to lansoprazole's potential to inhibit CYP1A2, increasing theophylline toxicity risk. Avoid in patients with hepatic impairment or acute asthma exacerbation. Taper theophylline to prevent withdrawal seizures.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take this medication exactly as prescribed, usually once daily in the morning.,Swallow the capsule whole; do not crush or chew.,Avoid drinking alcohol or consuming grapefruit products while on this medication.,Report symptoms like nausea, vomiting, palpitations, or seizures immediately.,Do not stop abruptly; consult your doctor for gradual dose reduction.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOPHYLLIN vs AEROLATE III, answered by our medical review team.
LANOPHYLLIN is a Bronchodilator that works by Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOPHYLLIN and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOPHYLLIN is: 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOPHYLLIN and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOPHYLLIN is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.